TY - JOUR
T1 - Variations in the promoter region of the glutaminase gene and the development of hepatic encephalopathy in patients with cirrhosis: A cohort study
AU - Romero-Gómez, Manuel
AU - Jover, María
AU - Del Campo, José A.
AU - Royo, José L.
AU - Hoyas, Elena
AU - Galán, José J.
AU - Montoliu, Carmina
AU - Baccaro, Eugenia
AU - Guevara, Mónica
AU - Córdoba, Juan
AU - Soriano, Germán
AU - Navarro, José M.
AU - Martínez-Sierra, Carmen
AU - Grande, Lourdes
AU - Galindo, Antonio
AU - Mira, Emilia
AU - Mañes, Santos
AU - Ruiz, Agustín
PY - 2010/9/7
Y1 - 2010/9/7
N2 - Background: Hepatic encephalopathy is a major complication of cirrhosis and is associated with a poor prognosis. Objective: To identify mutations in the gene sequence for glutaminase in humans that could be responsible for the development of hepatic encephalopathy in patients with cirrhosis. Design: Cohort study. Setting: Outpatient clinics in 6 Spanish hospitals. Patients: 109 consecutive patients with cirrhosis in the estimation cohort, 177 patients in the validation cohort, and 107 healthy control participants. Measurements: Patients were followed every 3 or 6 months until the development of hepatic encephalopathy or liver transplantation, death, or the end of the study. Results: The genetic analyses showed that glutaminase TACC and CACC haplotypes were linked to the risk for overt hepatic encephalopathy. Mutation scanning of the glutaminase gene identified a section in the promoter region where base pairs were repeated (a microsatellite). Over a mean follow-up of 29.6 months, hepatic encephalopathy occurred in 28 patients (25.7%) in the estimation cohort. Multivariable Cox models were used to determine the following independent predictors: Child-Turcotte-Pugh stage (hazard ratio [HR], 1.6 [95% CI, 1.29 to 1.98]; P = 0.001), minimal hepatic encephalopathy (HR, 3.17 [CI, 1.42 to 7.09]; P = 0.006), and having 2 long alleles of the microsatellite (HR, 3.12 [CI, 1.39 to 7.02]; P = 0.006). The association between 2 long alleles of the microsatellite and overt hepatic encephalopathy was confirmed in a validation cohort (HR, 2.1 [CI, 1.17 to 3.79]; P = 0.012). Functional studies showed higher luciferase activity in cells transfected with the long form of the microsatellite, which suggests that the long microsatellite enhances glutaminase transcriptional activity. Limitation: Other genes and allelic variants might be involved in the clinical expression of hepatic encephalopathy. Conclusion: This study identifies a genetic factor that is associated with development of hepatic encephalopathy in patients with cirrhosis. Primary Funding Source: Instituto de Salud Carlos III, Spanish Ministry of Health. © 2010 American College of Physicians.
AB - Background: Hepatic encephalopathy is a major complication of cirrhosis and is associated with a poor prognosis. Objective: To identify mutations in the gene sequence for glutaminase in humans that could be responsible for the development of hepatic encephalopathy in patients with cirrhosis. Design: Cohort study. Setting: Outpatient clinics in 6 Spanish hospitals. Patients: 109 consecutive patients with cirrhosis in the estimation cohort, 177 patients in the validation cohort, and 107 healthy control participants. Measurements: Patients were followed every 3 or 6 months until the development of hepatic encephalopathy or liver transplantation, death, or the end of the study. Results: The genetic analyses showed that glutaminase TACC and CACC haplotypes were linked to the risk for overt hepatic encephalopathy. Mutation scanning of the glutaminase gene identified a section in the promoter region where base pairs were repeated (a microsatellite). Over a mean follow-up of 29.6 months, hepatic encephalopathy occurred in 28 patients (25.7%) in the estimation cohort. Multivariable Cox models were used to determine the following independent predictors: Child-Turcotte-Pugh stage (hazard ratio [HR], 1.6 [95% CI, 1.29 to 1.98]; P = 0.001), minimal hepatic encephalopathy (HR, 3.17 [CI, 1.42 to 7.09]; P = 0.006), and having 2 long alleles of the microsatellite (HR, 3.12 [CI, 1.39 to 7.02]; P = 0.006). The association between 2 long alleles of the microsatellite and overt hepatic encephalopathy was confirmed in a validation cohort (HR, 2.1 [CI, 1.17 to 3.79]; P = 0.012). Functional studies showed higher luciferase activity in cells transfected with the long form of the microsatellite, which suggests that the long microsatellite enhances glutaminase transcriptional activity. Limitation: Other genes and allelic variants might be involved in the clinical expression of hepatic encephalopathy. Conclusion: This study identifies a genetic factor that is associated with development of hepatic encephalopathy in patients with cirrhosis. Primary Funding Source: Instituto de Salud Carlos III, Spanish Ministry of Health. © 2010 American College of Physicians.
U2 - 10.7326/0003-4819-153-5-201009070-00002
DO - 10.7326/0003-4819-153-5-201009070-00002
M3 - Article
SN - 0003-4819
VL - 153
SP - 281
EP - 288
JO - Annals of Internal Medicine
JF - Annals of Internal Medicine
IS - 5
ER -